Barker C C, Butzner J D, Anderson R A, Brant R, Sauve R S
Department of Pediatrics, University of British Columbia, Vancouver, British Columbia, Canada.
Bone Marrow Transplant. 2003 Jul;32(1):79-87. doi: 10.1038/sj.bmt.1704069.
The incidence, risk factors and mortality of veno-occlusive disease (VOD) were identified for 142 pediatric hematopoietic stem cell (HSC) transplant recipients with hematological malignancies (83), solid tumors (41) and nonmalignant diseases (18). This historical cohort of 142 HSC transplant patients, from January 1993 through June 2000, was assessed by chart review. Risk factors for the development of VOD and mortality were assessed by multiple logistic regression and Kaplan-Meier survival curves respectively. The incidence of VOD was 18.3% (26/142 transplants). Multivariate analysis reconfirmed the known pretransplant risk factors of induction therapy with busulfan and transplantation with matched unrelated donor cells as significant risk factors for the development of VOD. In addition, two new risk factors, positive CMV serology in the recipient and TPN provided in the 30 days prior to transplant, were identified. Mortality in transplant patients at 100 days was greater in the VOD-positive group (10/26 (38.5%)) compared to the VOD-negative group (11/116 (9.5%) (P=0.001)). The risk of death was 4.97 times higher with 95% CIs (2.11, 11.71) for the VOD-positive group. Decreasing the risk factors for VOD may decrease mortality in this patient population.
对142例患有血液系统恶性肿瘤(83例)、实体瘤(41例)和非恶性疾病(18例)的儿科造血干细胞(HSC)移植受者的静脉闭塞性疾病(VOD)的发病率、危险因素和死亡率进行了研究。通过查阅病历对这一1993年1月至2000年6月期间的142例HSC移植患者的历史队列进行了评估。分别通过多因素logistic回归和Kaplan-Meier生存曲线评估VOD发生的危险因素和死亡率。VOD的发病率为18.3%(26/142例移植)。多变量分析再次证实,已知的移植前危险因素如白消安诱导治疗和与匹配的无关供体细胞进行移植是VOD发生的重要危险因素。此外,还确定了两个新的危险因素,即受者CMV血清学阳性和移植前30天内给予的全胃肠外营养(TPN)。VOD阳性组移植患者100天时的死亡率(10/26(38.5%))高于VOD阴性组(11/116(9.5%)(P=0.001))。VOD阳性组的死亡风险高4.97倍,95%可信区间为(2.11,11.71)。降低VOD的危险因素可能会降低该患者群体的死亡率。